Justice Department Reschedules Medical Marijuana, Eases Federal Restrictions
Federal officials moved state-licensed medical marijuana from the most restrictive drug classification, providing tax relief and research opportunities for cannabis businesses.
ATLANTA, GEORGIA — The U.S. Department of Justice announced Thursday it will move state-licensed medicinal marijuana products from the federal government’s most restrictive drug classification, marking a shift in federal cannabis policy that could benefit Georgia’s medical marijuana program.
The order, signed by acting Attorney General Todd Blanche, transfers many marijuana products from Schedule I to Schedule III under the Drug Enforcement Administration’s classification system. Schedule I designates drugs with the greatest potential for abuse and least legitimate medical use, while Schedule III includes substances with accepted medical uses and moderate potential for dependence.
Tax Benefits and Research Opportunities
The reclassification will provide financial relief to state-licensed medical marijuana businesses, which will now be able to deduct business expenses from their federal taxes. Previously, these companies faced significant tax burdens due to their Schedule I status.
“The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options,” Blanche said in a statement. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.”
The policy change also opens new research possibilities. Under the previous Schedule I classification, only cannabis grown in federal facilities could be studied by researchers, severely limiting the supply available for scientific investigation. Now researchers will have access to state-legal products for their studies.
Broader Reclassification Process Ahead
The Justice Department also scheduled a comprehensive hearing on broader marijuana reclassification to begin June 29 and conclude no later than July 15. This hearing will examine the possibility of rescheduling marijuana products that could include recreational use, potentially affecting the drug’s federal status beyond medical applications.
The order applies specifically to state-licensed medical marijuana products in states that have legalized medicinal cannabis use. Georgia legalized low-THC cannabis oil for certain medical conditions in 2015 and has gradually expanded its medical marijuana program to include dispensaries and cultivation facilities.
Implementation and Limitations
Thursday’s announcement follows President Donald Trump’s executive order last year directing the Department of Justice to move toward rescheduling marijuana. The directive represented a fulfillment of campaign promises to address federal cannabis policy.
However, the reclassification likely will not immediately resolve banking challenges that marijuana businesses have faced. Financial institutions that serve cannabis companies have historically been reluctant to provide services due to federal restrictions, and it remains unclear whether Schedule III status will significantly change banking practices in the short term.
The policy change affects only medical marijuana products that operate under state licensing programs. Recreational marijuana remains federally illegal, and the upcoming summer hearing will determine whether broader changes to cannabis classification might follow.
For Georgia patients who rely on medical marijuana for qualifying conditions, the federal policy shift could lead to increased research into treatment effectiveness and potentially expanded access to different cannabis-based medications as more companies enter the market with improved tax treatment.
